Tina deVries
2018
In 2018, Tina deVries earned a total compensation of $551.4K as EVP, Research & Development at RVL Pharmaceuticals plc, a 6% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $147,443 |
|---|---|
| Salary | $392,808 |
| Other | $11,125 |
| Total | $551,376 |
deVries received $392.8K in salary, accounting for 71% of the total pay in 2018.
deVries also received $147.4K in non-equity incentive plan and $11.1K in other compensation.
Rankings
In 2018, Tina deVries' compensation ranked 11,555th out of 14,244 executives tracked by ExecPay. In other words, deVries earned more than 18.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,555 out of 14,244 | 19th |
Division Manufacturing | 4,668 out of 5,765 | 19th |
Major group Chemicals And Allied Products | 1,769 out of 2,128 | 17th |
Industry group Drugs | 1,505 out of 1,817 | 17th |
Industry Pharmaceutical Preparations | 1,156 out of 1,391 | 17th |
Source: SEC filing on April 26, 2019.
deVries' colleagues
We found three more compensation records of executives who worked with Tina deVries at RVL Pharmaceuticals plc in 2018.
News
RVL Pharmaceuticals plc Former EVP, Research & Development Tina deVries' 2022 pay slips 19% to $561K
April 24, 2023
RVL Pharmaceuticals plc CEO Brian Markison's 2021 pay falls 63% to $1.4M
April 25, 2022
RVL Pharmaceuticals plc CEO Brian Markison's 2020 pay slips 12% to $3.8M
April 26, 2021
RVL Pharmaceuticals plc CEO Brian Markison's 2019 pay jumps 291% to $4.3M
April 20, 2020
RVL Pharmaceuticals plc CEO Brian Markison's 2018 pay slips 10% to $1.1M
April 26, 2019